Moderna, Inc, 200 Technology Square, Cambridge, MA 02139, United States of America.
Moderna, Inc, 200 Technology Square, Cambridge, MA 02139, United States of America.
J Control Release. 2021 Jul 10;335:237-246. doi: 10.1016/j.jconrel.2021.05.021. Epub 2021 May 18.
Lipid nanoparticles (LNP) are effective delivery vehicles for messenger RNA (mRNA) and have shown promise for vaccine applications. Yet there are no published reports detailing how LNP biophysical properties can impact vaccine performance. In our hands, a retrospective analysis of mRNA LNP vaccine in vivo studies revealed a relationship between LNP particle size and immunogenicity in mice using LNPs of various compositions. To further investigate this, we designed a series of studies to systematically change LNP particle size without altering lipid composition and evaluated biophysical properties and immunogenicity of the resulting LNPs. While small diameter LNPs were substantially less immunogenic in mice, all particle sizes tested yielded a robust immune response in non-human primates (NHP).
脂质纳米颗粒 (LNP) 是信使 RNA (mRNA) 的有效递送载体,在疫苗应用方面显示出了潜力。然而,目前还没有发表的报告详细说明 LNP 的生物物理特性如何影响疫苗的性能。在我们的研究中,对体内 mRNA LNP 疫苗的回顾性分析表明,在使用不同组成的 LNP 时,LNP 颗粒大小与小鼠的免疫原性之间存在关系。为了进一步研究这一点,我们设计了一系列研究来系统地改变 LNP 粒径而不改变脂质组成,并评估所得 LNP 的生物物理特性和免疫原性。虽然小直径 LNP 在小鼠中的免疫原性显著降低,但所有测试的粒径在非人类灵长类动物 (NHP) 中均产生了强大的免疫反应。